Skip to main content
Premium Trial:

Request an Annual Quote

Source BioScience Purchases Two Illumina GAIIx; Plans to Install HiSeq 2000 this Year


UK service provider Source BioScience has purchased two Illumina Genome Analyzer IIx systems and plans to bring the firm's HiSeq 2000 technology in house later this year, the company said this week.

Source BioScience said it has invested a total of £700,000 ($1.13 million) in the two systems and ancillary equipment, which will be housed in its Nottingham facility. It has had an Illumina GA since 2008.

In addition to the instrument purchase, Illumina has designated Source BioScience as a CSPro-certified service provider for its sequencing technology.

Source BioScience provides diagnostic and screening services to the healthcare community, and genetic analysis and biomolecular tools to life science researchers as well as pharma and biotech companies.

The company, which is headquartered in Nottingham and has other labs in London, Cambridge, Oxford, and Dublin, offers both Sanger and next-generation DNA sequencing services and bioinformatics support.

In 2007, Geneservice, a contract research service provider based in Cambridge, became part of Source BioScience.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.